Danaher (NYSE:DHR) Shares Rebound 50% From Post-Earnings Drop, Yet $100 Million Delay Puts Recovery to Test

Danaher slid 10.99% on July 21, while the S&P 500 advanced 0.89%. Danaher ranked as the day’s steepest decliner on the index, reflecting a stock-specific reaction. Investing.com Investors cited disappointment with Q3 core growth guidance of 2%–3%. Barron’s noted Wall Street was looking for 3.6% in that period. While published consensus numbers were marginally different, Danaher surpassed both reported targets. Guidance for the year tightened to a 3%–4% range from 3%–6%, putting the spotlight on outlook rather than the quarterly result. Barron’s

On Friday, July 24, the most recent confirmed closing price was $191.50. This reflected a 7.0% increase from Tuesday’s close of $179.01, but the shares were still 4.8% under Monday’s pre-earnings close of $201.11. At the end of trading Friday, the company’s market value was about $135.5 billion. While the recovery is notable, the stock has not reached its pre-earnings level. Investing.com

Revenue rose 5.5% to $6.265 billion, with core revenue up 3.0%. Adjusted earnings climbed 8.0%, reaching $1.94 per share. GAAP net earnings stood at $870 million, equivalent to $1.23 per diluted share. Operating cash flow came in at $1.534 billion, while free cash flow amounted to $1.265 billion. Free cash flow registered a 15.5% gain, underlining a strong quarter financially. Danaher Corporation Investors

Biotechnology core sales rose 2.5% for the quarter. Executives attributed the modest rise to key customers postponing some shipments past June. Bioprocessing orders climbed at a solid mid-teens pace, even as shipments lagged. Demand for consumables strengthened, and China emerged as the fastest-growing geography in the segment. These data points back management’s rationale on shipment timing, yet evidence for a Q3 rebound is still lacking. Danaher Corporation Investors

Danaher’s Life Sciences segment posted 5.5% core growth, generating $1.879 billion in sales. Core growth in Diagnostics was 2.0%, or 5.0% excluding respiratory testing. Diagnostics revenue increased 7.0% to $2.466 billion, with Masimo making a significant contribution. Diagnostics pricing declined 1.5%, primarily because of China’s procurement program and promotions. While these two segments provided meaningful offset, performance did not meet Biotechnology expectations. Danaher Corporation Investors

The projected full-year core growth is now between 3% and 4%, narrowed from the prior 3% to 6% range. The midpoint dropped by a full point to 3.5%. At the same time, adjusted EPS guidance has been raised to a range of $8.45 to $8.60, up from $8.35 to $8.55. This moved the midpoint up by $0.075, or about 0.9%, aided in part by Masimo’s deal closing earlier than expected. Management maintains its outlook for total core growth to reach the mid-single digits in Q4. Danaher Corporation Investors

Danaher reported Q2 core growth of 3.0%, increasing to 4.5% when respiratory tests are excluded. The company projects respiratory sales for 2026 at about $1.6 billion, down from $1.9 billion. Q3 respiratory revenue is forecast near $325 million, compared to $500 million a year earlier. Q3 core growth is expected in the 2%–3% range, while core growth excluding respiratory is seen around 5%. This adjustment, while still a non-GAAP metric, offers a clearer view of base demand. Danaher Corporation Investors

Danaher closed its acquisition of Masimo on June 10 for roughly $9.8 billion in cash. Masimo reported revenue of about $1.5 billion during 2025. Management projects adjusted EPS will increase by $0.15–$0.20 in the first full year following the deal. Annual cost synergies of more than $125 million are targeted. Danaher recorded preliminary goodwill of around $5.0 billion. According to the 10-Q filing, several legal contingencies from before the acquisition are still pending, creating uncertainty. QuoteMedia

Total debt increased to $26.558 billion, up from $18.418 billion at the end of the year. Cash and equivalents stood at $4.348 billion, resulting in about $22.2 billion in net debt. Free cash flow for the first half rose 9.0% to $2.350 billion. Danaher met all debt covenants, with no borrowings on its main revolver. Liquidity remains sufficient, but significant deleveraging depends on continued cash generation. QuoteMedia

Shares at $191.50 are priced at approximately 22.5 times the midpoint of adjusted earnings guidance. The current trailing GAAP price-earnings multiple stands near 34 times earnings. This is less expensive than prior to the earnings report, but still not at distressed levels. The $0.40 dividend is set for payment on July 31 to shareholders on record as of June 26, offering an annualized yield of about 0.84% based on Friday’s close. Short-term share movement is expected to depend on updates to analyst estimates and the status of delayed bioprocessing shipments. The key issue remains: will those orders be fulfilled? Danaher Corporation Investors